These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32121290)

  • 1. Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
    Vivaldi C; Catanese S; Massa V; Pecora I; Salani F; Santi S; Lencioni M; Vasile E; Falcone A; Fornaro L
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
    Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
    JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
    Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A good start of immunotherapy in esophageal cancer.
    Zhao Q; Yu J; Meng X
    Cancer Med; 2019 Aug; 8(10):4519-4526. PubMed ID: 31231980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
    Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for esophageal cancer: a 2019 update.
    Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
    Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies.
    Casari C; Novysedlak R; Vachtenheim J; Lischke R; Strizova Z
    Pharmacology; 2023; 108(1):37-46. PubMed ID: 36463853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
    Alsina M; Moehler M; Lorenzen S
    Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
    De Mello RA; Lordick F; Muro K; Janjigian YY
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():237-247. PubMed ID: 31099644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives.
    Nagata Y; Yamamoto S; Kato K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2143177. PubMed ID: 36375821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors.
    Ma S; Chen F
    Pathol Res Pract; 2022 Oct; 238():154110. PubMed ID: 36155325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Park R; Williamson S; Kasi A; Saeed A
    Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
    Bhalla S; Doroshow DB; Hirsch FR
    Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immunotherapy for the treatment of esophageal cancer.
    Jackie Oh S; Han S; Lee W; Lockhart AC
    Expert Opin Investig Drugs; 2016 Jun; 25(6):667-77. PubMed ID: 26950826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
    Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.
    Balmaceda NB; Kim SS
    J Gastrointest Cancer; 2024 Mar; 55(1):153-167. PubMed ID: 38127239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Potentiality of Immune Checkpoint Inhibitors for Advanced Esophageal and Gastric Cancer].
    Muro K
    Gan To Kagaku Ryoho; 2016 Sep; 43(9):1041-7. PubMed ID: 27628545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.